IMMUNOLOGICAL MONITORING The core was initiated at the beginning of the last funding period. It provides tissue processing services and immune monitoring assays for cancer center members. The daily operations are under the supervision of Joel Whitfield who is the manager of the core. Two full-time research associates perform the core functions. During the last four years, 24 different users have utilized the service. Over 19,500 samples have been processed/assayed during this period. Recharges are developed for individual users to cover costs of laboratory supplies and labor. The core services are listed below. Services: Tissue processing and cryopreservation. This unique service involves isolation of peripheral blood monocytes (PBMC) or plasma from blood samples (i.e., blood draws or aphaeresis products);cryopreservation of PBMC or plasma/serum;tumor dispersion of solid tumors into single cell suspensions;cryopreservation of tumor samples;RNA or DNA extraction of tissue samples. These services to not duplicate the services of the Tissue Core. Storage of cryopreserved tissue samples Staining of PBMCs with monoclonal antibodies for phenotypic analysis by FACS (analysis to be provided by Flow Cytometry Core located in close proximity to the Immunology Core) ELISA assays of cytokines (murine and human IFN-y, GM-CSF, IL-10, IL-4, IL-6, TNF-a) Lymphocyte proliferation assays (i.e., KLH, tumor cells, mutagens) Mixed lymphocyte reaction (MLR) assays ELISPOT assays of cytokines (murine and human): The core has an automated spot reading for the ELISPOT assay. It also has the software necessary to analyze ELISPOT data which allows investigators to quantitate how many lymphoid cells secrete a specific cytokine in a response to antigen on a per cell basis. Lymphocyte cytokine release assays to antigens (i.e., tumor antigen or KLH) Lymphocyte cytoxicity assays to tumor targets (i.e., 4-hour chromium release assay) Quantitative RT-PCR for cytokine mRNA analysis of tissue samples.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-23
Application #
8147791
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
23
Fiscal Year
2010
Total Cost
$54,015
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Rosselli-Murai, Luciana K; Yates, Joel A; Yoshida, Sei et al. (2018) Loss of PTEN promotes formation of signaling-capable clathrin-coated pits. J Cell Sci 131:
Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Cilliers, Cornelius; Menezes, Bruna; Nessler, Ian et al. (2018) Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cancer Res 78:758-768
Lorenz, Daniel A; Vander Roest, Steve; Larsen, Martha J et al. (2018) Development and Implementation of an HTS-Compatible Assay for the Discovery of Selective Small-Molecule Ligands for Pre-microRNAs. SLAS Discov 23:47-54
Zhou, Bing; Hu, Jiantao; Xu, Fuming et al. (2018) Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem 61:462-481
Cho, Chun-Seok; Park, Hwan-Woo; Ho, Allison et al. (2018) Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation. Hepatology 68:1331-1346

Showing the most recent 10 out of 1493 publications